Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00483756 · ClinicalTrials.gov registry record · Phase 2

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

A Phase 2 study of Kidney Transplantation, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
338
Enrollment target
20
Study locations

NCT00483756 is a Phase 2 study of Kidney Transplantation that has completed, run by Pfizer. The registered enrollment target is 338 participants, above the 258-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (31% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00483756, a Phase 2 study of Kidney Transplantation, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
338 participants
Enrollment target
20
Study locations

Study Summary

A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months. Patients will be assigned to one of three treatment groups after receiving a kidney transplant. Two of the treatment groups will receive 2 different dosing regimens of the JAK3 inhibitor that will be taken by mouth. The third treatment group will be a standard-of-care control arm. Patients will continue to take the assigned study medication for 12 months as well as other standard transplant medications such as prednisone.

Conditions Studied

Kidney Transplantation

Interventions

  • DRUG Cyclosporine
  • DRUG CP-690,550

Study Locations (20)

California

  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Palo Alto
  • Pfizer Investigational Site - San Diego
  • Pfizer Investigational Site - San Francisco
  • Pfizer Investigational Site - San Francisco
  • Pfizer Investigational Site - Stanford

Florida

  • Pfizer Investigational Site - Gainesville
  • Pfizer Investigational Site - Gainsville
  • Pfizer Investigational Site - Tampa

Massachusetts

  • Pfizer Investigational Site - Boston
  • Pfizer Investigational Site - Springfield
  • Pfizer Investigational Site - Springfield

Connecticut

  • Pfizer Investigational Site - New Haven
  • Pfizer Investigational Site - New Haven

Illinois

  • Pfizer Investigational Site - Chicago
  • Pfizer Investigational Site - Chicago

Arkansas

  • Pfizer Investigational Site - Little Rock

Colorado

  • Pfizer Investigational Site - Aurora

Maryland

  • Pfizer Investigational Site - Baltimore

Trial Details

FieldValue
Enrollment Target 338 participants
Start Date 2007-08
Est. Completion 2010-04
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00483756

The ClinicalTrials.gov registry entry for NCT00483756 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 258-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (31% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Kidney Transplantation appearing as the primary indexed condition, and to 2 interventions - of which Cyclosporine is the first listed.

NCT00483756 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00483756 about?

NCT00483756 is a clinical study titled "Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients". A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months. Patient...

What is the current status of trial NCT00483756?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2007-08. Estimated completion is 2010-04.

What conditions does trial NCT00483756 study?

This clinical trial studies the following conditions: Kidney Transplantation.

What interventions are being tested in trial NCT00483756?

The interventions under investigation include: Cyclosporine (DRUG), CP-690,550 (DRUG).

Who is sponsoring clinical trial NCT00483756?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00483756 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Kidney Transplantation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Kidney Transplantation

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.